Research Summary

At O’VISTA, we began by establishing a rigorous, open-science foundation for early Alzheimer’s disease detection through a systematic, cross-paradigm meta-analysis of timing-resolved eye-movement biomarkers. Registered with PROSPERO (CRD420251024408) and publicly archived on Zenodo, our research quantified robust oculomotor deficits—particularly in antisaccade latency and error rate—that reliably distinguish Alzheimer’s patients from healthy aging controls (pooled Hedges’ g = 1.22; AUC ≈ 0.81).

Critically, we translated these findings into clinically actionable thresholds, providing transparent, locally calibratable decision-support rules to guide real-world deployment.

Building on this evidence base, we developed an integrated AI-powered platform that combines high-precision eye-tracking with real-time cognitive analytics. Our system delivers non-invasive, affordable, and scalable risk assessment—detecting subtle neurological changes years before clinical symptoms emerge.

To ensure accessibility and reliability, we also engineered and manufactured our own hardware, featuring research-grade tracking fidelity packaged in a user-friendly clinical interface.

Today, O’VISTA operates not as a diagnostic tool, but as a triage and monitoring solution—designed to work alongside standard cognitive evaluations, support early intervention, and enable longitudinal tracking of cognitive health in at-risk populations.